AI clinical trial feasibility tool market seen reaching $2.76 billion by 2030

The Business Research Company says the artificial intelligence clinical trial protocol feasibility tool market will grow from $0.83 billion in 2025 to $2.76 billion by 2030, driven by demand for faster trial approvals, lower costs and better protocol planning. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - AI feasibility tools are becoming a bigger part of clinical trial planning as drug developers look for faster approvals, lower costs and fewer trial failures. - The market forecast points to sustained demand for software that can predict recruitment, assess protocol risk and improve trial design. - Precision medicine is adding pressure for more tailored trial designs, which makes data-driven feasibility analysis more valuable.

What happened: - The Business Research Company released its Artificial Intelligence Clinical Trial Protocol Feasibility Tool Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report estimates the market will rise from $0.83 billion in 2025 to $1.06 billion in 2026. - The report projects the market will reach $2.76 billion by 2030. - The forecast implies a 27.3% CAGR in the historical period and a 27.0% CAGR through 2030. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - AI clinical trial protocol feasibility tools use algorithms to analyze historical clinical data, patient demographics and trial design factors. - The tools are designed to judge whether a proposed trial is feasible. - Core functions include predicting patient recruitment capacity, identifying protocol risks and optimizing trial design. - The report says growth has been supported by more complex trial protocols, higher failure rates, wider use of data-driven feasibility analysis, expanding clinical research activity and early adoption of AI planning tools. - Future growth is expected to be supported by quicker trial approvals, broader use of decentralized clinical trial models, AI-enabled protocol optimization platforms, lower trial costs and stronger predictive feasibility modeling. - The report highlights emerging use cases including protocol risk assessment, predictive recruitment modeling, integration of historical trial data, cloud-based feasibility solutions and trial design optimization. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The report also includes key technology analysis and future trend analysis. - The business posted sample and full-report links for more information: free sample report and the full market report.

Between the lines: - Precision medicine is helping drive demand because targeted therapies require more exact patient matching and trial design. - In 2023, 43% of the 217 oncology therapies approved by the FDA involved precision oncology treatments. - The report says 78 of those therapies incorporated DNA- or next-generation sequencing-detectable biomarkers. - That mix of regulatory and scientific complexity favors tools that can model recruitment, timelines and risk before a trial starts.

What's next: - The market is expected to keep expanding as sponsors adopt more AI-based planning tools and decentralized trial models. - Vendors will likely compete on better prediction models, richer historical data integration and cloud-based workflows. - The report suggests continued demand for protocol optimization platforms as clinical research becomes more data-intensive.

The bottom line: - AI-powered feasibility tools are moving from a niche planning aid to a core part of clinical trial strategy, and the market outlook points to rapid multi-year growth.